分享好友 资讯首页 频道列表

Galderma Unveils ‘Wake Up To Restylane’, Underscoring Restylane as the Ideal Hyaluronic Acid Treatment for Always-On Natural Beauty

2026-01-30 11:2119490

‘Wake Up To Restylane’ is a global campaign designed to meet the rising demand for natural-looking always-on results, helping people wake up looking refreshed and rested, and reframes Restylane treatments from a clinical procedure into an always-on beauty regimen
Backed by 30 years of science, the Restylane portfolio is the only hyaluronic acid (HA) range offering four distinct technologies, designed to deliver personalized natural-looking outcomes that provide contour, definition, and hydration, with HA closest to the skin’s own1-7
This launch builds on new clinical data presented at the International Master Course on Aging Science (IMCAS) World Congress 2026, confirming Restylane’s proven efficacy and versatility across multiple facial areas and the décolletage8-11

ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, has launched ‘Wake Up To Restylane’, a global campaign that showcases Restylane as an everyday beauty ally. Aligned with the growing desire for effortless, authentic results that restore facial balance and improve skin quality, the campaign highlights Restylane’s unique ability to deliver personalized results that move naturally with expressions to help people look and feel good.1,6,12-18

The launch was unveiled at the IMCAS World Congress 2026 in Paris, where Galderma also presented new clinical data reinforcing Restylane’s efficacy across key facial areas such as the chin, jawline, temples, as well as the décolletage, underscoring its unique position as the only HA portfolio offering a variety of formulations for tailored outcomes.1,8-11

 

“What's compelling about ‘Wake Up To Restylane’ is its focus on beauty that’s ready when you are. Patients increasingly want treatments that fit seamlessly into their lives, and this campaign captures that shift perfectly. For practitioners, Restylane continues to set the benchmark for HA treatments and remains an indispensable tool in modern aesthetic practice thanks to its proven science, unmatched versatility and reliability, and personalized, natural-looking results.”

 

DR. KULDEEP MINOCHA

AESTHETIC PHYSICIAN

L’ART BY DR M

 

 

As HA treatments remain the go-to for modern beauty, Restylane helps people wake up ready to go

‘Wake Up To Restylane’ captures a growing desire to look subtly refreshed – like you slept well – without the effort, especially towards beauty-conscious consumers, some of whom might be new to injectables, and want results that look authentic and harmonious, while aligning with their lifestyles. Restylane delivers what skincare and makeup alone can’t: structure, definition, balance, and a lasting glow, thanks to its unique HA that works in sync with your skin.1,6,12-18

Insights from Galderma’s research of over 4,300 consumers and healthcare professionals (HCPs) across four countries (Brazil, China, Germany and the United States) highlight the relevance of this campaign.12 HA treatments remain an important aesthetic treatment option, with about a third of consumers ranking HA as their top injectable choice ahead of neuromodulators.12 HA treatments remain among the most planned procedures globally, which signals the durable relevance and trust in the category.12

HAs are often chosen for deeply personal reasons: people describe HA treatments as an act of selfcare and selflove, a little indulgence in a stressful life that helps them feel comfortable in their own skin.12 Many are choosing HA specifically to improve skin quality, seeking healthy, glowing, hydrated skin that looks refreshed.12 Patients and practitioners align on naturallooking results, delivered safely and with reliable outcomes.12 This aligns perfectly with Restylane’s promise: authentic beauty that’s ready when you are, supported by three decades of safety data.1-3

 

“Restylane has an iconic heritage as a trusted, science-backed HA treatment, and ‘Wake Up To Restylane’ is an exciting evolution in how we connect the brand with evolving beauty aspirations. We’re not just responding to change – we’re leading it – driving the category forward, including for those taking their first steps into aesthetics, while staying true to the authentic always-on beauty and personalization that define the brand."

 

GERRY MUHLE

HEAD OF GLOBAL PRODUCT STRATEGY

GALDERMA

 

 

Restylane: Backed by science and designed differently, with proven versatility across facial areas and skin concerns

The versatile portfolio of Restylane HA treatments is designed to meet diverse patient needs across key areas of the face and décolletage, from soft, flexible formulations that smooth facial lines and wrinkles for a more youthful look, to firmer gels that provide contouring and structural support.2,5-11,13-21

Ongoing clinical evidence continues to reinforce Restylane’s ability to deliver natural-looking, long-lasting results across multiple indications.8-11 New clinical data presented at IMCAS demonstrated the efficacy of Restylane Shaype™ in shaping the chin, Restylane Lyft™ in improving jawline definition, and Restylane Volyme™ in correcting hollowing of the temples, while Restylane Skinboosters™ improved skin quality and smoothed wrinkles in the décolletage – an area often affected by sleep lines.8-11

With over 30 years of innovation and more than 77 million treatments administered worldwide, Restylane remains highly relevant in addressing some of today’s most significant aesthetic trends and needs, from facial changes following medication-driven weight loss to growing concerns related to menopause and skin health.1,22-24 Galderma’s continued innovation underscores its commitment to helping people feel good in their skin at every life stage.

About the Restylane portfolio

Restylane hyaluronic acid (HA) treatments are designed differently to go beyond volumizing for natural-looking results.1,25-27 Our HA is minimally modified and our innovative manufacturing process preserves its biocompatibility while creating individual products designed for a specific purpose.12,28-30 Powered by NASHA®, NASHA HD™, OBT™ and SB-NASHA™ technologies, Restylane offers gels with the highest firmness to the highest flexibility, enabling personalized treatments that deliver structural support, natural-looking results, and a healthy glow.4-7 Trusted for almost three decades, our HA gels work in sync with your skin for 100% natural-looking results.1-3

About Galderma

Galderma (SIX: GALD) is the pure-play dermtology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.

References

  1. Di Gregorio C, et al. 25+ years of experience with the Restylane portfolio of injectable HA fillers for facial aesthetic treatment. E-poster presented at AMWC; March 27-29, 2024; Monaco.
  2. Solish N, et al. Dynamics of HA fillers formulated to maintain natural facial expression. J Cosmet Dermatol. 2019;18(3):738-746. doi: 10.1111/jocd.12961.
  3. Philipp‐Dormston WG, et al. Perceived naturalness of facial expression after HA filler injection in nasolabial folds and lower face. J Cosmet Dermatol. 2020;19(7):1600-1606. doi: 10.1111/jocd.13205.
  4. Galderma Data on file. MA-56724. X-strain and G’ including Shaype.
  5. Nikolis A, et al. Effectiveness and Safety of a New Hyaluronic Acid Injectable for Augmentation and Correction of Chin Retrusion. J Drugs Dermatol. 2024;23(4):255–261. doi: 10.36849/JDD.8145.
  6. Öhrlund Å et al. Differentiation of NASHA and OBT Hyaluronic Acid Gels According to Strength, Flexibility, and Associated Clinical Significance. J Drugs Dermatol. 2024;23(1):1332–1336. doi: 10.36849/JDD.7648.
  7. Belmontesi M et al. Injectable Non-Animal Stabilized Hyaluronic Acid as a Skin Quality Booster: An Expert Panel Consensus. J Drugs Dermatol. 2018;17(1):83–88.
  8. Nikolis A, et al. A new NASHA-HD, high G’ hyaluronic acid (HA) injectable evaluated for chin treatment in combination with lower face and mid-face HA filler treatment. Poster presented at IMCAS 2026; January 29-31, 2026; Paris, France.
  9. Rivers J, et al. Effectiveness and safety of Restylane® Lyft™ Lidocaine for jaw-line definition: A 12-month randomized controlled study. Poster presented at IMCAS 2026; January 29-31, 2026; Paris, France.
  10. Moradi A, et al. Effectiveness and safety of a hyaluronic acid skin quality injectable for the correction of wrinkles in the décolletage area. Poster presented at IMCAS 2026; January 29-31, 2026; Paris, France.
  11. Nestor, M. Safety and effectiveness of an OBT™ hyaluronic acid filler for temple hollowing treatment: a randomized, controlled, clinical investigation. Poster presented at IMCAS 2026; January 29-31, 2026; Paris, France.
  12. Galderma. Data on file. Global report: Aesthetics treatments and hyaluronic acid injectables. Consumers & HCPs. 2025.
  13. Restylane® Shaype™. IFU. August 2023. Available online. Accessed January 2026.
  14. Restylane® Lyft™. IFU. August 2023. Available online. Accessed January 2026.
  15. Restylane®. IFU. August 2023. Available online. Accessed January 2026.
  16. Restylane® Eyelight™. IFU. August 2023. Available online. Accessed January 2026.
  17. Lee BM, et al. Rejuvenating Effects of Facial Hydrofilling using Restylane Vital. Arch Plast Surg. 2015;42(3):282–287. doi: 10.5999/aps.2015.42.3.282.
  18. Distante F, et al. Stabilized hyaluronic acid of non-animal origin for rejuvenating the skin of the upper arm. Dermatol Surg. 2009;35(S)1:389-394. doi: 10.1111/j.1524-4725.2008.01051.x.
  19. Hilton S, et al. Randomized, Evaluator-Blinded Study Comparing Safety and Effect of Two Hyaluronic Acid Gels for Lips Enhancement. Dermatol Surg. 2018;44(2):261–269. doi: 10.1097/DSS.0000000000001282.
  20. Restylane® Skinboosters Vital Lidocaine™. IFU. August 2022. Available online. Accessed January 2026.
  21. Restylane® Skinboosters Vital Light Lidocaine™. IFU. August 2021. Available online. Accessed January 2026.
  22. Galderma. Data on file. MA-57232 [Updated]. 77 Million treated.
  23. Fabi SG, et al. The potential role of biostimulators/dermal fillers to address menopause-related skin conditions. Poster presented at IMCAS 2026; January 29-31, 2026; Paris, France.
  24. Lorenc ZP, et al. Synergistic Efficacy and Safety of Poly-L-Lactic Acid Biostimulator and Hyaluronic Acid Filler for Facial Fullness post Weight Loss due to Glucagon-like Peptide-1 Receptor Agonist Medication. Presented at the ASDS 2025 Annual Meeting; November 13-16; Chicago, United States.
  25. Restylane. U.S. Instructions for use. Available online. Accessed January 2026.
  26. Nikolis A, Enright KM, Lazarova D, et al. The role of clinical examination in midface volume correction using hyaluronic acid fillers: should patients be stratified by skin thickness? Aesthet Surg J Open Forum. 2020;2(1):1–12. doi: 10.1093/asjof/ojaa005.
  27. Talarico S, et al. High patient satisfaction of a HA filler producing enduring full-facial volume restoration: an 18- month open multicenter study. Dermatol Surg. 2015;41:1361–1369. doi: 10.1097/DSS.0000000000000549.
  28. Edsman K, et al. Gel properties of hyaluronic acid dermal fillers. Dermatol Surg. 2012;38:1170–1179. doi: 10.1111/j.1524-4725.2012.02472.x.
  29. Galderma. Data on file. MA-58650. Degree of modification of HA fillers.
  30. Seo K. Facial volumization with fillers. Springer. 2021;29–83. doi: 10.1007/978-981-33-6212-3_2.

 

Contacts

For further information:
Christian Marcoux, M.Sc.
Chief Communications Officer
christian.marcoux@galderma.com
+41 76 315 26 50

Richard Harbinson
Corporate Communications Director
richard.harbinson@galderma.com
+41 76 210 60 62

Céline Buguet
Franchises and R&D Communications Director
celine.buguet@galderma.com
+41 76 249 90 87

Emil Ivanov
Head of Strategy, Investor Relations, and ESG
emil.ivanov@galderma.com
+41 21 642 78 12

Jessica Cohen
Investor Relations and Strategy Director
jessica.cohen@galderma.com
+41 21 642 76 43

Wake Up to Restylane Infographic

Restylane Media Backgrounder

反对 0
举报 0
收藏 0
打赏 0
评论 0
Microsoft与Postel合作推出创新的新数据和AI驱动解决方案,优化意大利中小企业与其客户的关系
罗马--(美国商业资讯)-- Microsoft与 Poste Italiane Group下属公司Postel宣布深化双方合作以及所签订有关意大利企业数字化业务的协议,新增Audiencerate成为双方在数据以及直接与数字营销领域的技术合作伙伴。 本新闻稿包含多媒体。此处查看新闻稿全文: https://www.businesswire.com/news/home/20260427939560/zh-CN/ 该协议涉及发布一个综合性的平台,将Postel的全渠道实体及数字传播能力...

0评论2026-04-301506

Alsym Energy宣布利用融合物理知识的人工智能平台成功开发出Na-Series电池
Alsym专有的物理知识人工智能平台为其Na-Series电池的开发提供了强大支持。该电池是一种不可燃、高性能、低成本的能源解决方案,旨在服务于关键储能市场,包括数据中心、公共事业、电信、商业地产、工业及国防等领域。 马尔登,马萨诸塞州--(美国商业资讯)--不可燃高性能钠离子电池领域的先锋企业Alsym Energy今日公布了用于开发公司最近推出的Na-Series钠离子电池的专有物理知识人工智能平台的详细信息。通过将基础物理模型与人工智能、自主测试及专有分子诊断技术集成于一个闭环系统中,A...

0评论2026-04-301257

Albion与Tecnotree合作,为TELUS提供面向北美市场的下一代增值服务平台
普莱恩维尤,纽约州--(美国商业资讯)--电信托管服务与解决方案领先供应商Albion今日宣布,TELUS已选定Albion与Tecnotree合作,共同提供新一代增值服务(VAS)平台,首批将部署语音信箱应用程序。 本新闻稿包含多媒体。此处查看新闻稿全文: https://www.businesswire.com/news/home/20260428959414/zh-CN/ 根据合作协议,Albion将利用Tecnotree久经考验的增值服务(VAS)和数字服务平台提供解决方案,...

0评论2026-04-301864

Samsung Bioepis and ATLATL Sign Memorandum of Understanding (MoU) to Accelerate Early-Stage Biotech Innovation in Asia-Pacific
INCHEON, Korea & SHANGHAI--(BUSINESS WIRE)--Samsung Bioepis Co., Ltd. and ATLATL Innovation Center (hereinafter referred to as "ATLATL"), global innovation platform for life science research and development, today announced that the c...

0评论2026-04-301509

LTM推出BlueVerse Studio,打造企业智能体AI应用中心
展示AI能力以解决客户面临的实际挑战 印度班加罗尔--(美国商业资讯)--全球最大规模企业的商业创意合作伙伴LTM今日宣布在班加罗尔推出BlueVerse Studio,这是一个旨在加速客户企业智能体AI应用并实现可衡量业务成果的枢纽。LTM持续在全球推出更多工作室以推动AI创新,目前在伦敦和孟买也设有同类工作室。 作为公司持续投资、让创新更贴近客户的一部分,BlueVerse Studio的创建旨在帮助客户将AI解决方案从实验扩展至实际应用,同时确保信任与控制。它将LTM最强的AI能力整...

0评论2026-04-301726

Thredd協助Clique推出邀約制財富生態系統及Visa卡方案
雙方的合作夥伴關係支援Clique在更廣泛的私人財富服務中推出Visa卡方案 新加坡--(美國商業資訊)-- Thredd是一個AI優先的髮卡處理平臺,該公司今日宣布與Clique Finance Limited(以下簡稱「Clique」)達成合作。Clique是一個採用邀約制的私人財富管理生態系統,專為企業家、家族辦公室以及擁有複雜跨境生活方式的高淨值人士設計,致力於提供超越傳統銀行業務框架的財富管理方案。 透過此次合作,Thredd與Clique將借助Visa消費信用卡,打造一種銜接數...

0评论2026-04-301423

NIQ洞察:亚太地区消费者在持续的不确定性中重新定义价值
由于不确定性持续存在,亚太地区消费者正在更加审慎地管理支出,这凸显了快消品品牌需要聚焦关注供应、定价纪律和清晰的价值传递。 新加坡--(美国商业资讯)--消费者情报领域的领导者NielsenIQ (NYSE: NIQ)今日分享最新洞察,基于其最新思想领导力报告《超越石油冲击:不确定世界中的快消品策略》(Beyond Oil Shocks: FMCG Strategies in an Uncertain World),探讨快消品品牌如何应对亚太地区持续的不确定性和不断演变的消费者期望。 在亚...

0评论2026-04-301110

Roquette将在2026年欧洲国际营养保健食品展上展示其扩展后的消费者健康解决方案能力
专家将在3F112展位分享面向消费者的日常健康创新解决方案洞察 法国里尔--(美国商业资讯)--作为植物基配料、赋形剂和药用解决方案领域的全球领导者,Roquette将于2026年5月5日至5月7日在巴塞罗那举行的2026年欧洲国际营养保健食品展上展示其扩展后的产品组合。Roquette的解决方案旨在助力消费者健康品牌前瞻布局未来,并加速以消费者为中心的日常健康创新。 本新闻稿包含多媒体。此处查看新闻稿全文: https://www.businesswire.com/news/home/2...

0评论2026-04-301152

Hytera to Host Global Partner Summit 2026 in Shanghai, Advancing AI-Powered Mission-Critical Communications
SHANGHAI--(BUSINESS WIRE)--Hytera Communications, a leading global provider of critical communications technologies and solutions, today announced it will host its highly anticipated Hytera Global Partner Summit (HGPS) 2026 in Shanghai on...

0评论2026-04-301332

Sun Pharma签署收购Organon的最终协议
Organon股东将获得每股14.00美元的现金 该交易对Organon的企业价值估值为117.5亿美元 合并后的业务将利用互补的产品组合和全球规模,实现可持续的长期价值创造 印度孟买、新泽西州泽西市--(美国商业资讯)-- Sun Pharmaceutical Industries Limited(Reuters:SUN.BO,Bloomberg:SUNP IN,NSE:SUNPHARMA,BSE:524715) (连同其子公司和/或关联公司,统称“Sun Pharma&rd...

0评论2026-04-301376